来自MSN14 小时
Piper Sandler Initiates Coverage of ResMed (RMD) with Neutral Recommendation
Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief ...